Prexasertib
- Generic Name
- Prexasertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N7O2
- CAS Number
- 1234015-52-1
- Unique Ingredient Identifier
- 820NH671E6
- Background
Prexasertib has been used in trials studying the treatment and basic science of mCRPC, Leukemia, Neoplasm, breast cancer, and Ovarian Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT02649764
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT02555644
- Locations
- πΊπΈ
University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States
π«π·Gustave Roussy, Villejuif Cedex, France
π«π·Centre Leon Berard, Lyon, France
A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT02514603
- Locations
- π―π΅
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 167
- Registration Number
- NCT02124148
- Locations
- πΊπΈ
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
πΊπΈTennessee Oncology PLLC, Nashville, Tennessee, United States
πΊπΈUniversity of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Phase 1 Study in Participants With Advanced Cancer
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2016-05-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 150
- Registration Number
- NCT01115790
- Locations
- πΊπΈ
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
πΊπΈTennessee Oncology PLLC, Nashville, Tennessee, United States
πΊπΈFlorida Cancer Specialists, Sarasota, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.